OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Luke on Current and Emerging Treatment Approaches in Metastatic Melanoma

January 7th 2020

Jason J. Luke, MD, FACP, discusses current and emerging treatment paradigms in metastatic melanoma.

Dr. Vulfovich on Molecular Testing in Colorectal Cancer

January 7th 2020

Michel Vulfovich, MD, discusses molecular testing in colorectal cancer.

The Development of Genetic Testing in Ovarian Cancer

January 7th 2020

Leigha Senter, MS, LGC, discusses the development of genetic testing in ovarian cancer.

Dr. Woyach on the Results of the ELEVATE-TN Trial in CLL

January 7th 2020

Jennifer Woyach, MD, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia.

Dr. Damon on Optimal Treatment Regimens in AYA ALL

January 6th 2020

Lloyd Damon, MD, discusses optimal treatment regimens in adolescent/young adult acute lymphoblastic leukemia.

Dr. Wang on the Benefit of BTK Inhibitors in MCL

January 6th 2020

Michael Wang, MD, discusses the benefit of BTK inhibitors in mantle cell lymphoma.

Dr. Alva on the Toxicity Profiles of TKIs in RCC

January 6th 2020

Ajjai Shivaram Alva, MBBS, discusses class-specific toxicities of TKIs in renal cell carcinoma.

Similarity of Biosimilars and Biologics

January 4th 2020

Thomas Helleday, PhD, professor of Translational Oncology, director of the Weston Park Cancer Centre, Department of Oncology and Metabolism, The Medical School, The University of Sheffield, discusses the similarity of biosimilars and biologics.

Dr. Lockhart on Next Steps for Regorafenib and TAS-102 in mCRC

January 4th 2020

A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

Dr. Vidal on the Use of CDK4/6 Inhibitors in HER2+ Breast Cancer

January 4th 2020

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.

Dr. Andreadis on Treatment Approaches in Relapsed MCL

January 4th 2020

Charalambos (Babis) Andreadis, MD, MSCE, discusses the need to identify an optimal standard of care in patients with relapsed/refractory mantle cell lymphoma.

Dr. Lazarides on Challenges in Moving the Field of Osteosarcoma Forward

January 4th 2020

Alexander Leandros Lazarides, MD, discusses some of the current challenges in moving the field forward in osteosarcoma.

Dr. Borghaei on Immune-Related Adverse Events in Lung Cancer

January 3rd 2020

Hossein Borghaei, DO, MS, discusses immune-related adverse events in patients with lung cancer who received immunotherapy/chemotherapy combinations.

Dr. Vaishampayan on the Role of Cytoreductive Nephrectomy in mRCC

January 3rd 2020

Ulka Vaishampayan, MD, professor of oncology at Wayne State University, and the chief of the Solid Tumor Program at Barbara Ann Karmanos Cancer Institute, discusses the current role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Dr. Heath on the Toxicity Profiles of Oral Antiandrogens in Nonmetastatic CRPC

January 3rd 2020

Elisabeth I. Heath, MD, FACP, discusses the safety profiles of apalutamide, enzalutamide, and darolutamide in nonmetastatic castration-resistant prostate cancer.

Dr. Moore on Treatment for Patients With Ovarian Cancer Who Develop Resistance to PARP Inhibitors

January 3rd 2020

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, discusses treatment for patients with ovarian cancer who progress on a PARP inhibitor.

Dr. Woyach on Frontline Treatment Options in CLL

January 3rd 2020

Jennifer Woyach, MD, discusses frontline treatment options for patients with chronic lymphocytic leukemia.

Dr. Vaishampayan on Immunotherapy Trials in Kidney Cancer

January 3rd 2020

Ulka Vaishampayan, MD, discusses trials that examine frontline immunotherapy for metastatic kidney cancer.

Dr. Martin on Subcutaneous Administration of Daratumumab in Multiple Myeloma

January 3rd 2020

Thomas G. Martin, MD, discusses the impact of subcutaneous administration of daratumumab on patients with early relapse multiple myeloma.

Dr. Wong on Investigational CAR T-Cell Products in Multiple Myeloma

January 3rd 2020

Sandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.